4//SEC Filing
Wallace Owen B. 4
Accession 0000899243-20-014416
CIK 0001680581other
Filed
May 27, 8:00 PM ET
Accepted
May 28, 4:16 PM ET
Size
8.8 KB
Accession
0000899243-20-014416
Insider Transaction Report
Form 4
Wallace Owen B.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2020-05-26$7.84/sh+412$3,230→ 127,500 total - Sale
Common Stock
2020-05-26$20.00/sh−412$8,240→ 127,088 total - Exercise/Conversion
Stock Option (right to buy)
2020-05-26−412→ 87,714 totalExercise: $7.84Exp: 2029-01-21→ Common Stock (412 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019.
- [F2]The shares underlying the option are scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022.
Documents
Issuer
Fulcrum Therapeutics, Inc.
CIK 0001680581
Entity typeother
Related Parties
1- filerCIK 0001778843
Filing Metadata
- Form type
- 4
- Filed
- May 27, 8:00 PM ET
- Accepted
- May 28, 4:16 PM ET
- Size
- 8.8 KB